Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy. Although the majority of patients initially respond to upfront chemotherapy, relapses with poor prognosis occur in approximately 20% of cases. Thus, novel therapeutic strategies are required to improve long-term survival. B-cell precursor (BCP)-ALL cells express low levels of immunogenic molecules and, therefore, are poorly recognized by the immune system. In the present study, we investigated the effect of various combinations of potent B-cell stimulators including CpG, Interleukin (IL)-2 family cytokines and CD40 ligand (CD40L) on the immunogenicity of primary BCP-ALL cells and a series of BCP-ALL cell lines. The combination of CpG, IL-4 and CD40L was identified as most effective to enhance expression of immunogenic molecules on BCP-ALL cells, resulting in an increased capacity to induce both allogeneic and autologous cytotoxic T lymphocytes (CTL). Importantly, such CTL exhibited significant anti-leukemic cytotoxicity not only towards treated, but also towards untreated BCP-ALL cells. Our results demonstrate that the combination of CpG with other B-cell stimulators is more efficient than CpG alone in generating immunogenic BCP-ALL cells and anti-leukemic CTL. Our results may stimulate the development of novel adoptive T cell transfer approaches for the management of BCP-ALL.
Introduction
Pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is the most common childhood malignancy, accounting for approximately 80% of all ALL cases, 1 with a 5-year-survival rate of over 80% after treatment. 2, 3 Still, up to 25% of pediatric ALL patients in remission have relapses. The prognosis of patients with relapsed leukemia and with high-risk factors is poor and therapy options are limited, 4 indicating a need for additional treatment approaches, particularly for those targeting residual leukemic cells.
BCP-ALL cells, like many malignant cells, express low levels of immunogenic surface molecules and are poor T-cell stimulators, which facilitates their escape from cellular anti-leukemic immune responses. [5] [6] [7] Some immunotherapeutic approaches aim at enhancing immunogenicity by increasing co-stimulatory and antigen-presenting signals of malignant cells to overcome the escape mechanisms. Although BCP-ALL cells exhibit only low levels of co-stimulatory and antigen-presenting molecules, they still express cytokine and toll-like receptors (TLRs), 8 rendering them potential targets for immunostimulatory agents, such as cytokines and TLR agonists.
One of the most abundant TLRs on B cells is TLR9. The classical ligands for TLR9 are CpG oligodeoxynucleotides (CpG), which contain motifs of unmethylated cytosine-phosphate-guanosine dinucleotides that mimic bacterial or viral DNA fragments. CpGstimulated normal B cells exhibit enhanced proliferation, cytokine production and upregulation of co-stimulatory molecules, 9 whereas malignant B cells hardly proliferate, but still develop an immunogenic phenotype that is better recognizable by immune cells than that of unstimulated cells. [10] [11] [12] In a murine xenograft model, CpG administration decreased leukemic burden 13 and induced durable remission and ongoing immune-mediated protection against leukemic growth, 14 but these advantageous effects of CpG have thus far not been translated into patients.
There is evidence that receptors for cytokines of the interleukin (IL)-2 family are expressed on normal B cells, B-chronic lymphocytic leukemia (B-CLL) cells and BCP-ALL cells. 15, 16 Furthermore, CpG may regulate these receptors on malignant leukemia cells. 17 The IL-2 receptor family shares the common cytokine receptor g-chain (CD132) and additional private receptor chains that are specific for the cytokines IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21, respectively. 18 IL-4, which is produced by T-helper cells, binds to IL-4R on B cells, a receptor that mediates activation, major histocompatibility complex (MHC) class II expression, Ig class switching and antibody secretion. In addition, there is evidence that IL-2 family cytokines can synergize in terms of their effects on B cells. For example, IL-4 and IL-21 cooperate in regulation of Ig classswitching to IgG1 and IgE. 19 CD154 (CD40 ligand; CD40L) is another ligand expressed by T-helper cells with potent B-cell stimulatory capacities. It binds to CD40, a tumor necrosis factor family member and costimulatory receptor expressed on B cells. CD40 has been shown to be induced by CpG in B cells and B-CLL cells 20 and its ligation leads to B-cell clonal expansion, antigen presentation, expression of co-stimulatory molecules, antibody secretion and cytokine production. 21 Interestingly, there are hints that dysfunctional expression of CD40L on bone marrow T cells in ALL patients contribute to the progression of disease, possibly by defective mutual crosstalk between ALL and T cells. [5] [6] [7] Approximately 15 years have passed since CpG was first considered as a potential therapy for chronic and acute lymphocytic leukemias. Unfortunately, the doses being used in-vivo are too low to induce immunogenic changes in leukemia cells, as serum proteins bind considerable amounts of CpG at doses around 0.5-1.0 mg/ml. 22 Moreover, even in-vitro, CpG alone often fails to trigger robust cellular immune responses against immunogenized leukemic cells. Therefore, the combined use of CpG with other B-cell stimulatory agents may significantly boost the immunogenic effect of CpG alone, 23 particularly when an ex-vivo approach is selected, where higher concentrations of such B-cell stimulatory agents may be used without the danger of adverse effects on other cells or the whole organism. Here, we demonstrate that the combination of CpG, CD40L and IL-4 is highly effective in inducing BCP-ALL immunogenicity, thereby exceeding the effect of CpG alone. Even more importantly, we find that the use of such pretreated BCP-ALL stimulator cells allows ex-vivo generation of allogeneic and autologous T cells with potent cytotoxic activity against both treated and untreated BCP-ALL cells.
Materials and methods

BCP cell lines, patient samples and xenograft ALL
Cell lines Nalm-6, Reh, KOPN-8 and MHH-CALL2 were purchased from DSMZ (German Collection of Microorganisms and Cell Cultures; Braunschweig, Germany), RS4;11 cells were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA). The BCP-ALL cell line 018Z was established in our laboratory. Leukemia samples were obtained at diagnosis from pediatric de-novo BCP-ALL patients enrolled into the ALL-BFM 2000 study protocol, 24 after informed consent was given. Peripheral blood samples from patients in remission were obtained together with routine diagnostic sampling, after informed consent was given. The study was approved by the Institutional Ethics Committee; animal experiments were approved by the appropriate authority at the University of Ulm. In order to raise sufficient numbers of identical BCP-ALL cells from each donor, some BCP-ALL cells were expanded in a murine xenograft model (Xeno-BCP-ALL cells) as initially described by Nijmeijer et al., 25 and as modified by Reid et al. 8 This model allowed us to expand and maintain viable BCP-ALL cells derived from patients, until these individuals had finished chemotherapy and were in remission. This enabled us to perform experiments using BCP-ALL cells and autologous cytotoxic T lymphocte (CTL) from the same patients. Briefly, unconditioned Non-Obese Diabetic (NOD)/LtSz-scid/scid mice were transplanted by intravenous injection of 1 Â 10 7 primary BCP-ALL cells per recipient and subsequently expanded in this system over several weeks. At clinical manifestation, leukemia mice were killed and leukemia cells isolated from the spleen. Cell suspensions consisted of more than 90% ALL cells, as determined by flow cytometry after costaining with monoclonal antibodies to human CD19, Ly-5 and CD10 (both BD Bioscience, Heidelberg, Germany). MHH-CALL2 cells, 018Z cells, primary BCP-ALL cells and Xeno-BCP-ALL cells were cultured in RPMI medium supplemented with 20% fetal bovine serum, 1% L-glutamine (Invitrogen, Carlsbad, CA, USA), HEPES buffer (Biochrom, Berlin, Germany) and sodium pyruvate (Biochrom). Medium for all other cell lines was supplemented with 10% fetal bovine serum.
Reagents for functional assays and in-vitro treatment of BCP-ALL cells Human IL-4 (400 U/ml) was purchased from PeproTech GmbH (Hamburg, Germany), IL-21 (100 ng/ml) was from BioSource (Camarillo, CA, USA). The type B CpG phosphorothioate oligodeoxynucleotide ODN 10104 (2.5 mg/ml, henceforth designated CpG) with the specific sequence 5 0 -TCG TCG TTTCGT CGT TTT GTC GTT-3 0 was purchased from Coley Pharmaceutical Group (Ottawa, Canada). Soluble CD40L monomer (1 mg/ ml) effect was increased by enhancer for ligands (1 mg/ml), 26 both purchased from Alexis Biochemicals (Enzo Life Sciences GmbH, Lö rrach, Germany). For T-cell stimulation, anti-CD3/ CD28 antibody-coated beads (0.25 ml per 200 ml per well) were used (Dynal, Invitrogen GmbH, Karlsruhe, Germany). Carboxyfluorescein diacetate succinimidyl ester (CFSE) was purchased from Molecular Probes (Eugene, OR, USA) and Na 51 CrO 4 for cytotoxicity assays from Amersham-Buchler (Braunschweig, Germany). To enhance their immunogenicity, various types of BCP-ALL cells were treated in vitro with CpG, CD40L, IL-4 and IL-21 for 48 h at the combinations indicated.
Flow cytometry
For fluorescence-activated cell sorting analysis, cells were harvested at the indicated time points and stained as described previously. 27 FITC-, PE-, PE-Cy5-, PerCP-Cy5.5-, PE-Cy7-, APCor AmCyan-labeled antibodies to CD3, CD4, CD8, CD10, CD19, CD40, CD54, CD86, MHC class I and MHC class II were purchased from Becton Dickinson (Heidelberg, Germany). Flow cytometric analyses were performed on a FACScan, a FACSCalibur or an LSRII (all from Becton Dickinson Immunocytometry Systems, San Jose, CA, USA) and data analyzed using FlowJo software (version 8.7.1; Tree Star, Stanford, CA, USA).
CFSE staining and proliferation assay
For co-culture experiments, peripheral blood mononuclear cells (PBMC) from healthy individuals were isolated using Ficoll density gradient centrifugation, after obtaining informed consent. Red blood cells were lysed according to standard procedures. PBMC were flow-cytometrically tested for CD3 þ T-cell counts to range between 60 and 80%, then resuspended in phosphate-buffered saline (1 Â 10 7 cells/ml) containing 1 mM CFSE, incubated at 37 1C for 10 min and washed three times. 2 Â 10 5 PBMC were cocultured for 5 days with allogeneic Xeno-BCP-ALL cells that had been pre-treated 48 h with various reagents as indicated. Cells were plated in 200 ml complete RPMI medium on 96-well roundbottom plates at a PBMC:ALL cell ratio of 10:1. PBMC cocultures with untreated Xeno-BCP-ALL cells, PBMC alone and Xeno-BCP-ALL cells alone served as controls. Flow cytometric analyses were performed by gating on viable CFSE low CD4 þ and CD8 þ T cells after exclusion of CD19 þ BCP-ALL cells.
Generation of CTLs and cytotoxicity assay
Alloreactive or autologous CTLs were generated by incubating PBMC from healthy donors (1 Â 10 6 /ml) with either untreated or pretreated stimulator BCP-ALL cells at an effector:stimulator (E:S) ratio of 10:1. Stimulation was performed in RPMI medium containing 10% pre-tested fetal calf serum and 30 U/ml rhIL-2, which was added at day 4 after each stimulation. Before stimulation, BCP-ALL cell lines were treated with mitomycin C (50 mg/ml) to suppress proliferation, whereas Xeno-BCP-ALL cells were used as stimulators without mitomycin C treatment, because of their limited survival in culture. Restimulation of CTLs with BCP-ALL cells was repeated every 7 days. Effector T cells were harvested at day 6 after stimulation and added to 51 Cr-labeled untreated BCP-ALL target cells at an E:T ratio of 50:1, serially diluted and incubated for 4 h at 37 1C. Supernatant of 50 ml was assayed in triplicates for 51 Cr-release in a Top
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CountNXT counter (Perkin Elmer, Rodgau-Jü gesheim, Germany) and results were expressed as specific lysis according to the following formula: Specific lysis (%) ¼ 100 Â ((average experimental releaseÀspontaneous release)/(maximum releaseÀ spontaneous release)).
Toll-like receptor 9 real time reverse transcription polymerase chain reaction (PCR)
For quantitative analysis of TLR9 mRNA expression, the BCP-ALL cell lines RS4;11, KOPN-8 and 018Z were incubated with CpG (2.5 mg/ml) in the presence or absence of CD40L (1 mg/ml) and IL-4 (400 U/ml) for 48 h, whereas untreated cells served as control. Total RNA was extracted from 2 Â 10 6 BCP-ALL cells per sample using an RNeasy mini kit (Qiagen, Hilden, Gemany), according to the manufacturer's protocol. Genomic DNA was digested with RNAse-free DNAse I set (Qiagen), cDNA synthesis of 1 mg total RNA was performed using RT Superscript III (Invitrogen, Carlsbad, CA, USA). Primers for TLR9 mRNA were as follows:
0 . PCR products were analyzed with a Light Cycler 2 (Roche, Mannheim, Germany) using the SYBR Green PCR kit (Qiagen). PCR signals were normalized to average expression of the housekeeping genes TATTA box-binding protein and RPL-32 by subtracting the mean cycle threshold 
Cytometric bead array
For cytokine quantification, four primary ALL samples were cultured with the indicated reagents for 48 h. Then supernatants were harvested and analyzed using a sandwich Bio-Plex cytokine immunoassay, following the manufacturer's specifications (Bio-Rad, Hercules, CA, USA). This assay permits simultaneous detection of IL-6, IL-10, IL-12 and tumor necrosis factor-a. All incubations were carried out at 24 1C. Briefly, the anti-cytokine bead solution was diluted and 50 ml placed on 96-well Durapore membrane plates (Millipore, Billerica, MA, USA). After washing by vacuum filtration, 50 ml of undiluted supernatants and standards were placed into wells and incubated for 1 h while shaking at 300 r.p.m. After washing, 25 ml detection antibody was added and incubated for another 30 min on the shaker. After washing, streptavidin-PE was added for 10 min. Then, plates were washed, resuspended in assay buffer, read on a flow cytometer (Luminex, Riverside, CA, USA) and analyzed using Bio-Plex Manager software (Bio-Rad).
Statistics
Data are expressed as means±s.e.m. To determine statistical differences between the means of two data columns, the paired two-tailed Student's t-test was used. P-values were corrected using the Bonferroni method, where applicable. Results with P-values o0.05 were considered significant.
Results
The combination of CpG, IL-4 and CD40L is more potent than CpG alone to induce an immunogenic BCP-ALL phenotype Recently, CpG was reported to exert stimulatory effects on two major lymphocytic leukemia entities including B-CLL 10, 11, 20, 28, 29 and BCP-ALL. 8, 13, 14 In the current study, we wished to extend this approach in human BCP-ALL cells by combining CpG with other B-cell stimulatory agents to further enhance BCP-ALL immunogenicity. The combination of CpG with cytokines of the IL-2 family has profound phenotypic effects on other B-cell leukemias, such as B-CLL. 17, 30 We, therefore, tested the effect of various cytokines of this family, including IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21. We also included CD40L into our study, as it represents another highly promising agent for immunotherapeutic approaches in BCP-ALL and B-CLL. [31] [32] [33] [34] After initial screening, we identified IL-4, IL-21 and CD40L as the most promising partners for CpG to induce an enhanced immunogenic BCP-ALL cell phenotype. Importantly, the basal expression of a panel of immunological cross-talk molecules including the adhesion molecule CD54, the co-stimulatory molecules CD40 and CD86, as well as the antigen-presenting molecules MHC class I and II, was highly variable among different types of BCP-ALL cells. The strongest effect of CpG on surface expression was found for CD54 and CD40, which both exhibited a rather weak basal expression compared with the other markers tested (Supplementary Figure 1) . Of note, the effects of IL-4, IL-21 and CD40L as single agents were rather mild, and only in combination with CpG, could they induce a synergistic enhancement of CD54 expression (Figures 1a, b and c). All other IL-2 family members were not capable of inducing substantial increase of molecules important for immunogenicity in combination with CpG (data not shown). The most effective combinations were identified as CpG plus IL-4 plus IL-21 and CpG plus IL-4 plus CD40L (Figures 1a, b and c). Although the overall upregulation of the various immune markers was highly heterogeneous throughout all BCP-ALL samples tested, similar effects with the two optimal combinations could be observed not only in BCP-ALL cell lines (Figure 1d ), but also in primary BCP-ALL cells from patients and in Xeno-BCP-ALL cells expanded in mice (Figure 1e) . Surprisingly, in some BCP-ALL samples, we found a consistent loss of viable cells when treated with the combination CpG plus IL-4 plus IL-21. Further testing revealed that the presence of IL-21 was responsible for this cell death (Supplementary Figure 2) . Although viable BCP-ALL cells may induce more robust and specific T-cell responses than non-viable BCP-ALL cells, that is, by the secretion of cytokines, we decided to focus mainly on the combination CpG plus IL-4 plus CD40L for the remainder of our study. This view was confirmed by our finding that BCP-ALL cells stimulated with CpG, IL-4 and CD40L showed a superior capacity to secrete pro-inflammatory cytokines including tumor necrosis factor-a and IL-12, as compared with unstimulated BCP-ALL cells or cells stimulated with the single agents (Supplementary Figure 3) .
Treatment of BCP-ALL cells with IL-4, CD40L and CpG results in the induction of TLR9 mRNA expression
In an attempt to identify a rationale for the enhanced potential of CpG to induce an immunogenic BCP-ALL cell phenotype in the presence of IL-4 and CD40L, we tested whether expression of the CpG receptor TLR9 that is constitutively expressed by B cells at high levels, 35 may be regulated by combining IL-4 and CD40L with CpG. For this purpose, we performed real-time reverse transcription PCR for TLR9 mRNA expression by the BCP-ALL cell lines 018Z, RS4;11 and KOPN-8, and found enhanced expression of TLR9 message in the presence of IL-4 and CD40L, as compared with untreated BCP-ALL cells or cells treated with CpG alone (Figure 2 
are more potent than BCP-ALL cells treated with CpG alone to induce allogeneic T-cell proliferation Efficient T-cell activation and expansion is a prerequisite for the establishment of a comprehensive anti-tumor immune response in vivo. We, therefore, studied the effect of differentially treated BCP-ALL cells on allogeneic T-cell proliferation. The two combinations, which were optimal for phenotypic activation, also proved to be the most efficient in inducing BCP-ALL cell immunogenicity. BCP-ALL cells treated with CpG plus IL-4 plus CD40L acquired the highest capacity to induce proliferation of allogeneic CD4
þ and CD8 þ T cells (Figures 3a and b) . Particularly in CD8 þ CTL, this combination, but not the combination CpG plus IL-4 plus IL-21, exhibited a significant advantage over stimulation with single agents including CpG alone (Figure 3b ). Untreated control BCP-ALL cells induced minimal T-cell proliferation. Similar results were obtained using an 3 H-thymidine assay instead of CFSE labeling (Supplementary Figure 4) .
BCP-ALL cells treated with CpG, IL-4 and CD40L trigger CTL-mediated anti-leukemic cytotoxicity towards allogeneic untreated BCP-ALL cells An efficient anti-tumor immune response requires that T cells are not only activated and expanded, but are able to actually kill tumor cells. We, therefore, used differentially treated BCP-ALL cells to raise BCP-ALL-specific CTLs. Subsequently, we used these CTLs to induce lysis in untreated BCP-ALL cells of the same type. Using RS4;11 and KOPN-8 cells in initial experiments demonstrated that when these cells were treated with CpG, IL-4 and CD40L, but not when they were left untreated or treated with CpG alone, they were able to generate CTLs that induced specific lysis in the corresponding untreated BCP-ALL cells (Figure 4a ). This confirmed once more, that the combined treatment of BCP-ALL cells with CpG, IL-4 and CD40L is indeed superior to treatment with CpG alone. Of note, third party BCP-ALL cells such as Nalm-6 or MHH-CALL2 were not lysed by KOPN-8-or RS4;11-specific CTLs, demonstrating that the killing occurred in an antigen-specific manner (Figure 4b ). Far lower CpG ODN, IL-4 and CD40L trigger enhanced BCP-ALL cell immunogenicity D Fabricius et al cytotoxicity was achieved with specific CTLs raised against the BCP-ALL cell line Nalm-6 (data not shown), reflecting their weaker immunophenotypic profile (Figure 1d ). Nevertheless, even with Nalm-6 cells as stimulators, a difference in cytotoxicity levels between CTLs raised against treated versus untreated Nalm-6 cells was detectable (data not shown).
To apply our results with CTLs raised against BCP-ALL cell lines onto primary cells, we repeated our experiments with CTLs CpG ODN, IL-4 and CD40L trigger enhanced BCP-ALL cell immunogenicity D Fabricius et al generated in the presence of allogeneic Xeno-BCP-ALL cells after expansion in NOD/Severe Combined Immunodeficiency (SCID) mice. Consistent with our results in BCP-ALL cell lines, we found that Xeno-BCP-ALL cells treated with CpG, IL-4 and CD40L exhibited a higher potency to generate specific CTLs than untreated Xeno-BCP-ALL cells (Figure 4c ). Of note, cytotoxicity of CTLs raised against treated BCP-ALL cells remained stable or even increased after repeated stimulations (black bars), a finding not observed in CTLs restimulated with untreated BCP-ALL cells (grey bars), which lost their lytic potential over time (Figure 4d ). To demonstrate specificity of CTLs for the BCP-ALL cells they were raised against, we performed another set of experiments, in which we used various control targets including PBMC from the CTL donor, PBMC from the stimulator ALL donor, as well as BCP-ALL cells from an irrelevant donor as a third party control. These experiments clearly showed that CTLs raised against a defined BCP-ALL cell clone were indeed specific for this clone and did not cross-react with non-ALL lymphocytes nor with BCP-ALL cells from a different donor (Figure 4e ).
Antileukemic cytotoxic effect of autologous CTLs generated from patients in remission directed against xenograft ALL cells derived from the corresponding diagnostic ALL sample Most importantly, we also investigated the anti-leukemic effect of CTLs raised against BCP-ALL cells treated with CpG, IL-4 and CD40L in an autologous setting, in which effector CTLs and Figure 3 Xeno-BCP-ALL cells treated with CpG, CD40L and IL-4 are more potent to induce T-cell proliferation than when treated with CpG alone. BCP-ALL cells were pretreated with CpG (2.5 mg/ml) alone or in combination with IL-4 (400 U/ml) and either IL-21 (100 ng/ml) or CD40L (1 mg/ml) along with an enhancer for ligands (1 mg/ml) for 48 h. Then, allogeneic PBMC were isolated, stained with CFSE and co-incubated for 5 days with pretreated, washed BCP-ALL cells at an ALL:PBMC ratio of 10:1. The percentages of CFSE target leukemia cells were derived from the same patient. Leukemia cell samples obtained at diagnosis from three individual pediatric BCP-ALL patients were expanded using the NOD/SCID/huALL model described above. 36 ALL cells were isolated from ALL-bearing recipients and were cryopreserved. Meanwhile, ALL patients were successfully treated and achieved continuous remission. PBMC were isolated from peripheral blood obtained from these patients 6 months after the end of anti-leukemic treatment. Corresponding ALL samples were re-passaged in the NOD/SCID/huALL model, and were used both for stimulation and as targets in our assay (Supplementary Figure 5) . Of note, treatment of primary BCP-ALL cells with CpG, IL-4 and CD40L significantly enhanced the cytotoxic capacity of autologous CTLs raised against them by 3-to 4-fold compared with untreated BCP-ALL cells. As may be expected in an autologous setting, maximum lysis achieved was lower than in the allogeneic setting (Figures 5a and b) . These results suggest that this approach may be used to target residual ALL cells in a clinical setting.
Discussion
In the current study, we showed for the first time that certain B-cell stimulatory agents including CpG, IL-2 family cytokines and CD40L can be combined to synergistically activate the immunophenotype of BCP-ALL cells. We identified CpG and the T-helper signals IL-4 and CD40L as a highly effective cocktail to induce an immunogenic phenotype in BCP-ALL cells, which far exceeds the effects of the single agents such as CpG alone. The effects observed included consistent upregulation of surface molecules such as CD40, CD54, CD86, MHC class I and class II, as well as secretion of the pro-inflammatory cytokines IL-12 and tumor necrosis factor-a. All these molecules are known to be important for antigen presentation, 37, 38 and some, like the adhesion molecule CD54, directly provide costimulation for cytotoxic CD8 þ T cells. 37 Consequently, we could demonstrate that BCP-ALL cells treated with this cocktail, but not untreated cells or cells treated with single agents only, gained the capacity to generate and expand leukemia-specific CTL in both allogeneic and autologous mixed lymphocyte cultures. These CTL exhibited specific cytotoxic activity not only towards activated BCP-ALL cells, but also towards untreated cells. The outcome of our experiments was independent of whether we used primary patient-derived BCP-ALL cells, Xeno-BCP-ALL cells or BCP-ALL cell lines, suggesting our results were not a consequence of cell culture-based artifacts.
An important question arising from our results is why the combination of B-cell stimulatory agents such as CpG, IL-2 cytokines and CD40L may be superior over the use of single agents to enhance leukemic B-cell immunogenicity. Previously, it was described that CpG can upregulate a variety of receptors including CD40, the binding partner of CD40L, or the receptors for IL-2 and IL-21, on B-CLL cells. 17, 20, 30 This finding could be confirmed in the present study for the expression of CD40 on BCP-ALL cells. In addition, we could demonstrate that expression of the receptor for CpG, TLR9, is also positively regulated by combined action of CD40L, IL-4 and TLR9 itself in BCP-ALL cells. Our results, therefore, suggest that the synergistic effects of CpG, IL-4 and CD40L are, at least in part, due to mutual upregulation of the respective binding partners for the compounds used.
Inclusion of IL-4 and CD40L into a highly effective B-cell immunogenic cocktail is substantiated by several additional characteristics of these mediators. Both CD40L and IL-4 are expressed by CD4
þ Th 2 cells and are integral part of an efficient Th 2 response. 39 Ligation of CD40 by T-helper cell-expressed CD40L mediates co-stimulation and induces cytokine production in antigen-presenting cells, including B cells in general. 21 Interestingly, the bone marrow of ALL patients often exhibits a predominance of CD4 þ Th 2 cells, which do not express CD40L or IL-2 receptor (CD25), thereby contributing to both increased-tumor cell escape and insufficient tumor cell control. 7 On the other hand, activation of pre-BCP-ALL cells via CD40 has earlier been described to overcome T-cell hyporesponsiveness 6 and, therefore, decisively contributes to a clinically relevant anti-tumor immune response. These findings are further supported by previous investigations in B-CLL, where CpG was shown to strongly increase responsiveness to CD40L by upregulation of CD40. 10 Moreover, recent observations revealed, that the combination of IL-4 with CD40L upregulated components essential for antigen presentation in ALL cells on the mRNA level. 40 All these studies, therefore, support the rationale to use CD40L and IL-4 as additional stimuli for the activation of BCP-ALL cells.
For the generation of CTL, no T-cell stimulatory agents except for IL-2 were used in our study, demonstrating that the enhanced immungenicity of BCP-ALL cells was the main responsible factor accounting for the induction and expansion of ALLspecific CTL. Similar to our findings, it was demonstrated earlier that ALL-specific CTL with both human leukocyte antigenrestricted and human leukocyte antigen-unrestricted reactivity could be efficiently generated in vitro by repeated stimulation of donor PBMC with ALL cells. 25 Subsequent administration of these ALL-specific CTL to NOD/SCID mice engrafted with human ALL cells resulted in complete or partial remissions. 25 These results clearly demonstrate the efficacy and feasibility of therapeutic adoptive T-cell transfer in NOD/SCID mice, although it remains to be determined whether its efficacy can be enhanced by the use of immunogenized ALL cells, as demonstrated in our in-vitro system. An important result of our study was that we achieved specific lysis of untreated human BCP-ALL cells not only with allogeneic, but also with autologous CTL. This could be of direct clinical relevance for the future development of such approaches, as the therapeutic use of autologous anti-leukemic CTL may result in prolonged graft-versus-leukemia responses. A potentially significant factor in our study was that we used PBMC rather than isolated T cells to generate ALL-specific CTL. This implies that other peripheral immune cells may have been involved in the generation of CTL, including dendritic cells, which may have taken up dying leukemia cells and presented a variety of leukemia cellassociated antigens to T cells. This scenario may resemble the in-vivo situation more closely than the use of highly purified and isolated cell subsets. Clearly, further studies are needed to shed more light into the involvement of different immune cells within our approach.
In this study, we used a well-characterized NOD/SCID mouse xenograft model to expand human BCP-ALL cells. This enabled us to investigate leukemia cells that resembled as closely as possible patient-derived BCP-ALL cells, an assumption supported by other laboratories. 41, 42 On the basis of our findings, we plan to use the same mouse model in a future study to investigate human BCP-ALL cells and corresponding CTL in a systemic setting. Earlier research, in which CpG was administered as a single treatment in vivo in an otherwise comparable NOD/SCID mouse xenograft model, pointed towards a strong potential of CpG oligodeoxynucleotides as therapeutic agents for the treatment of BCP-ALL, because CpG induced a potent allogeneic Th 1 response 8 and reduced leukemic burden in the mice. 13 However, the anti-leukemia effect was at least partially mediated by residual murine natural killer cells in the NOD/ SCID mice. Using Balb/c mice and Em-Ret fusion proteintransgenic ALL cells, the same group could demonstrate that CpG may be beneficial also in a autologous context and may even mediate protection from ALL. 14 We are, therefore, optimistic that using BCP-ALL cells pretreated with the immunogenic cocktail identified in the present study will allow us to provide in-vivo proof-of-principle for the proposed adoptive T-cell transfer approach.
Direct enhancement of malignant cell immunogenicity is one potential approach to prevent the escape of leukemia cells from an efficient immune response. 43 In vivo attempts to apply B-cell stimulators such as CpG in patients to induce such a response have been rather disappointing so far. Strong binding of CpG to CpG ODN, IL-4 and CD40L trigger enhanced BCP-ALL cell immunogenicity D Fabricius et al serum proteins may be one reason that free CpG levels in patients are not sufficient to induce phenotypic changes in malignant cells. 22 The adoptive T-cell transfer approach proposed here may be able to resolve this problem. Instead of applying immunomodulators in vivo, patient-derived immune cells including CTL may be 'trained' and expanded ex vivo by stimulation with activated leukemia cells, before being re-infused into the patient. An additional advantage of such an Figure 5 Xeno-BCP-ALL cells stimulated with CpG, IL-4 and CD40L induce autologous T cell-mediated cytotoxicity towards untreated Xeno-BCP-ALL cells. Xeno-BCP-ALL cells expanded in NOD/SCID mice were harvested and either treated with CpG (2.5 mg/ml), IL-4 (400 U/ml) and CD40L (1 mg/ml) or left untreated for 48 h. At the same time, autologous PBMC from the original BCP-ALL patients were isolated during the remission phase and used to generate CTLs. CTLs were stimulated for 7 days with either treated or untreated autologous BCP-ALL cells. The effector PBMC:stimulator BCP-ALL ratio was 10:1. IL-2 (30 U/ml) was added to CTLs at day 4 of each stimulation cycle. Chromium release assay was performed at day 6 by incubation of CTLs with untreated CpG ODN, IL-4 and CD40L trigger enhanced BCP-ALL cell immunogenicity D Fabricius et al approach over vaccinations with single leukemia-associated peptides would be, that the induced immune response would be polyclonal rather than oligo-or monoclonal. Anti-leukemic human leukocyte antigen-matched allogeneic CTL clones have already been established, 44 although it was shown that such T cells alone are not sufficient to elicit efficient graft-versusleukemia activity. 45 Therefore, in-vitro pretreatment of patientderived leukemia cells with immunogenic 'cocktails' before their use as stimulators for allogeneic or even autologous CTL may be a promising alternative to enhance the efficacy of such approaches.
In conclusion, we have demonstrated in the present study that pre-treatment of BCP-ALL cells with a cocktail containing CpG, CD40L and IL-4 profoundly enhances the immunogenicity of these cells, thereby substantially exceeding the effects of these agents alone. Of note, such immunogenic BCP-ALL cells can be efficiently used to generate both allogeneic and autologous CTL with specific cytotoxic activity towards treated and untreated BCP-ALL cells. Clearly, further studies in a NOD/SCID-based systemic setting need to confirm the efficacy of an adoptive T-cell transfer approach as proposed by our work. Our current investigations, as well as further studies based on the results presented here, may be a first step towards novel immunotherapeutic approaches to the management of BCP-ALL.
